The Guide to VAT for Clinical Trials in Europe aims at:

Dear readers Hope you had a good start into 2019. As you may already gathered through the press the referendum for the Swiss Tax Bill and AHV-Financing (Steuervorlage und AHV-Finanzierung – STAF) has been launched with success. The respective popular vote will take place in spring, i.e. on 19 May 2019. A lot of pharma […]

Dear all, Happy to invite you to have a look to our latest PwC Webinar on precision medicines and the respective hot topics in the VAT field for the US, Europe, Switzerland and Asia.

I am pleased to invite you to our Webinar on Precision Medicine and Accurate Indirect Tax

My recommendation on your next steps: Choose a holistic approach in order to assess and possibly optimise the health of your value chain (tax, legal, regulatory, operational, digital etc.). Use “scientific” out of the box thinking, innovation and an efficient delivery model as the tools to success.

Are you a pharmaceutical company selling drugs outlined in the list of special drugs and therapies (“Spezialitätenliste”) in Switzerland? If yes, you could benefit from the following information in connection with Swiss VAT.

Have you already heard about the new medical drug ordinance in Switzerland – especially about Art. 21?

A ghost is haunting Europe – the possible content of Annex 21 EU Good manufacturing practice (“GMP”). This is the most important information in a nutshell.